Published in BMC Cancer on July 20, 2016
Advances in sarcoma diagnostics and treatment. Oncotarget (2016) 0.75
Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol (2005) 4.80
Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res (2005) 3.23
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res (2006) 2.84
FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res (2002) 2.71
Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J (1995) 2.67
The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res (1997) 2.62
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
FoxM1 is a general target for proteasome inhibitors. PLoS One (2009) 2.34
FOXM1: From cancer initiation to progression and treatment. Biochim Biophys Acta (2011) 2.32
Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol (2006) 2.11
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis. PLoS One (2009) 1.93
Molecular analysis of a novel winged helix protein, WIN. Expression pattern, DNA binding property, and alternative splicing within the DNA binding domain. J Biol Chem (1997) 1.86
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton. Nat Chem (2011) 1.82
Retracted FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Breast Cancer Res Treat (2009) 1.57
Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer (2009) 1.45
A novel FoxM1-caveolin signaling pathway promotes pancreatic cancer invasion and metastasis. Cancer Res (2011) 1.45
Catalytic function of DNA topoisomerase II. Bioessays (1991) 1.43
The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol (2012) 1.40
Identification of cell cycle-regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors. Mol Biol Cell (2013) 1.29
The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis (2010) 1.28
Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer (2009) 1.26
The central role of CDE/CHR promoter elements in the regulation of cell cycle-dependent gene transcription. FEBS J (2009) 1.23
Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res (2011) 1.23
FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis (2012) 1.22
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res (2011) 1.20
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res (2012) 1.19
Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett (2004) 1.18
Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol (2003) 1.17
Forkhead box M1 expression in pulmonary squamous cell carcinoma: correlation with clinicopathologic features and its prognostic significance. Hum Pathol (2009) 1.16
Suppression of FOXM1 sensitizes human cancer cells to cell death induced by DNA-damage. PLoS One (2012) 1.15
Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol (1995) 1.13
Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Invest (1992) 1.10
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer (2012) 1.04
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer (2005) 1.04
FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer. Acta Histochem (2012) 1.04
CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol Cell Biol (2008) 1.00
Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur J Cancer (2008) 0.96
FOXM1 is an oncogenic mediator in Ewing Sarcoma. PLoS One (2013) 0.94
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat (2014) 0.92
Identification of FoxM1/Bub1b signaling pathway as a required component for growth and survival of rhabdomyosarcoma. Cancer Res (2012) 0.89
Detection of fusion gene transcripts in fresh-frozen and formalin-fixed paraffin-embedded tissue sections of soft-tissue sarcomas after laser capture microdissection and rt-PCR. Diagn Mol Pathol (2003) 0.88
Differential expression of forkhead box M1 and its downstream cyclin-dependent kinase inhibitors p27(kip1) and p21(waf1/cip1) in the diagnosis of pulmonary neuroendocrine tumours. Histopathology (2012) 0.85
Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients. Clin Transl Oncol (2013) 0.82
Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia. Cancer Lett (2015) 0.82
Cell-cycle-dependent regulation of the human and mouse Tome-1 promoters. FEBS Lett (2005) 0.81
Up-regulation of the DR5 expression by proteasome inhibitor MG132 augments TRAIL-induced apoptosis in soft tissue sarcoma cell lines. Cancer Res Treat (2011) 0.80
Glypican 3 expression in pediatric malignant solid tumors. Eur J Pediatr Surg (2014) 0.79
FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target. Tumour Biol (2015) 0.75
Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line. Cancer Sci (2016) 0.75